Fredric Cohen, M.D.
Fredric 'Fred' Cohen, M.D. is founder and president of Pharma Growth Strategies, LLC, a specialized management consultant to the pharmaceutical and biopharmaceutical industries. PGS' service offerings include business development, research and development strategy and planning, marketing strategy and lifecycle management.
Prior to forming PGS in 2004, Dr. Cohen held positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, most recently as Senior Director, Drug Development and Strategic Development Leader for the emerging endocrine and metabolic area franchise. Prior to J&J, Fred held strategic and business development positions at Eli Lilly and Company.
He is author/editor of Pharma's Cutting Edge, a popular web log devoted to the pharmaceutical industry.
Fredric Cohen, M.D.'s Latest Articles
-
Notable Advance in Monitoring Molecular Response to Cancer Therapy
on Jul 07, 2008
- In GLP-1 Wars, Novo & Others Knock at Amylin’s Door; Find Amylin Moved to Pricier Digs
- Evaluating Cancer Drugs at the FDA
-
Not Enough Progress on Google Patent Search
on May 04, 2008 about GOOG
-
Sirtris Employees Are Feeling Valued
on Apr 28, 2008 about GSK
-
GSK Buys Sirtris Pharma for $9 million Per Employee
on Apr 24, 2008 about GSK
- Experts Weigh in on ENHANCE Published Results
- Consumers Union’s Approach to Improving Drug Safety Surveillance is Misguided
- Grassley Seeks GAO Input on Surrogates and Postmarketing Follow Up by FDA
-
Alnylam Stakes Claim to 1st Human Demo of Activity for RNAi Therapy
on Mar 09, 2008 about ALNY
-
GTx Phase 3: A Win for Prostate Cancer Sufferers and for Entrepreneurism
on Feb 27, 2008
- Understanding the Medtronic Case Decision
- A PR Virus for Pharmaceuticals
- Top 7 BioPharma & Pharma Innovations of 2007
-
Eli Lilly: It’s That We Were Told That’s Telling
on Oct 25, 2007 about LLY
-
FDA Non-Approval of Merck's Arcoxia Legitimate
on Aug 17, 2007 about MRK
-
Drug Pricing and the Incentives to Innovate
on Jul 30, 2007
- Ariad Pharmaceuticals vs. Eli Lilly: When Will the Insanity End?
-
ClinPage Corrects Its Story On Pfizer Site Recruitment Strategy
on Jul 12, 2007 about PFE
- Did I Speak Too Soon About The Demise of NPY Blockers?
- Chronic Use of Rimonabant: Risk-Benefit Analysis Underway
-
Dendreon: Without Background On FDA's Process, All Is Speculation
on May 10, 2007 about DNDN
-
A Few Lessons From Exubera
on Apr 18, 2007 about PFE
-
Conference Call With Alexion Leaves Credit Suisse Analyst Speechless
on Mar 28, 2007 about ALXN
-
Eli Lilly Advances Study of PPAR-alpha Agonist
on Mar 28, 2007 about LLY
- The FDA's Decision on Galvus
- Glaxo and HGS's Announcement: Reading Between the Lines
-
Sanofi-Aventis: FDA Lays to Rest Metabolic Syndrome Indication for Acomplia
on Feb 20, 2007 about SNY
-
FDA-VA Memorandum of Understanding Will Not Appease Critics
on Feb 05, 2007
- Top Pharma Innovations In 2006
-
Sanofi-Aventis Investors Take Note: Senate Confirms Von Eschenbach as FDA Commissioner
on Dec 08, 2006 about SNY
-
Simply Tragic: Pfizer's Torcetrapib Cholesterol Drug Halted
on Dec 04, 2006 about PFE
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
- About Seeking Alpha
- About Us
- Contact Us
- What's New
- Readers Feedback
- Contributors
- Contribute an Article
- Feature Your Book
- Our Contributors
- Anonymous Contributions
- Dispute an Article?
- Tools & Widgets
- Stock Market Toolbar
- Stock Search Add-on
- Power Search
- Email Alerts
- Live Feeds (RSS)
- Legal
- Terms of Use
- Privacy
- Copyright
- Advertise
Want to talk to our community?
Got something interesting to say?
- Advertise with Us
Latest Commentson Fredric Cohen, M.D.'s Articles